Mylan's capacity will rise to 50 bn doses in APAC during 2012

What is the current status of the research collaboration with Biocon? By when do you see this partnership reaching fruitition?We are pleased with the progress of this collaboration. We have five products in development and will begin clinical development this year, and expect to launch our first products in 2014-15 for developing markets and 2015-16 for developed markets.

Can you elaborate about your arrangement with Gilead Life Sciences?Mylan has licensed the rights to produce and market generic versions of Gilead HIV/AIDS therapies, consisting of single and fixed-dose combinations containing Emtricitabine. Emtricitabine is marketed by Gilead under the brand name Emtriva, and a fixed-dose combination of emtricitabine and tenofovir disoproxil fumarate is available under the brand name Truvada. Emtricitabine also is an essential component of the "Quad," an investigational treatment which combines four Gilead medicines in a once-daily, single tablet regimen for the treatment of HIV.

Lastly what are the challenges that you currently facing in the Indian market?As with any market, healthcare policies, including pricing and reimbursement are keys in driving growth. Currently, discussions are taking place in India on increasing its expenditures on health, including providing universal health care, which depending on the exact scope of the changes and implementation, could contribute to accelerated growth.